Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces G₂/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells

Oncol Rep. 2015 May;33(5):2639-47. doi: 10.3892/or.2015.3871. Epub 2015 Mar 20.

Abstract

Styrylquinazolines are synthetic analogues of resveratrol and have been suggested to cause anti-inflammatory activity by modulating prostaglandin E₂ (PGE₂) production. In the present study, we evaluated cytotoxic effects of various styrylquinazoline derivatives and found that (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline (8-ADEQ) most potently inhibited the proliferation of the human cervical carcinoma HeLa cells. Exploring the growth-inhibitory mechanisms of 8-ADEQ, we found that it causes a cell cycle arrest at the G₂/M phase by DNA flow cytometric analysis, which was accompanied by upregulation of cyclin B1 expression and cyclin-dependent protein kinase 1 (Cdk1) phosphorylation. In addition, we observed that 8-ADEQ causes phosphorylation of the cell division cycle 25C (Cdc25C) protein through the activation of checkpoint kinases 1 (Chk1) and Chk2, which in turn were activated via ataxia telangiectasia mutated (ATM)/ataxia telangiectasia-Rad3-related (ATR) kinases in response to the DNA damage. Furthermore, ATM/ATR inhibitor caffeine, p53- or ATM/ATR-specific siRNA significantly attenuated 8-ADEQ-induced G₂/M arrest. These results suggest that the 8-ADEQ inhibits the proliferation of human cervical cancer HeLa cells by DNA damage-mediated G₂/M cell cycle arrest. 8-ADEQ‑induced G₂/M arrest is mediated by the activation of both Chk1/2-Cdc25 and p53-p21CIP1/WAF1 via ATM/ATR pathway, and indicates that 8-ADEQ appears to have potential in the treatment of cervical cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ataxia Telangiectasia Mutated Proteins / genetics*
  • CDC2 Protein Kinase
  • Carcinoma / genetics
  • Cell Cycle Checkpoints / drug effects*
  • Cell Cycle Checkpoints / genetics
  • Cell Division / drug effects*
  • Cell Division / genetics
  • Checkpoint Kinase 1
  • Checkpoint Kinase 2 / genetics
  • Cyclin B1 / genetics
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinases / genetics
  • DNA Damage / drug effects
  • DNA Damage / genetics
  • Female
  • G2 Phase / drug effects*
  • G2 Phase / genetics
  • HeLa Cells
  • Humans
  • Phosphorylation / drug effects
  • Phosphorylation / genetics
  • Protein Kinases / genetics
  • Quinazolines / pharmacology*
  • Resveratrol
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Stilbenes / pharmacology
  • Tumor Suppressor Protein p53 / drug effects
  • Tumor Suppressor Protein p53 / genetics
  • Up-Regulation / drug effects
  • Up-Regulation / genetics
  • Uterine Cervical Neoplasms / genetics*
  • cdc25 Phosphatases / genetics

Substances

  • CDKN1A protein, human
  • Cyclin B1
  • Cyclin-Dependent Kinase Inhibitor p21
  • Quinazolines
  • Stilbenes
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Protein Kinases
  • Checkpoint Kinase 2
  • ATM protein, human
  • ATR protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • CHEK1 protein, human
  • CHEK2 protein, human
  • Checkpoint Kinase 1
  • CDC2 Protein Kinase
  • CDK1 protein, human
  • Cyclin-Dependent Kinases
  • CDC25C protein, human
  • cdc25 Phosphatases
  • Resveratrol